Indeed, current case report literature has demonstrated some utility in treatment of PEComas with mTOR inhibitors, such as rapamycin and sirolimus, which function to inhibit mTOR, which, as aforementioned, is activated in PEComas [5, 11, 12]. This evidence concerns the gene MTOR and neoplasm with perivascular epithelioid cell differentiation.